Related Experiment Videos
Meningococcal vaccines
Clare L Collins1, Andrew J Pollard
1Department of Paediatrics, University of Oxford, John Radcliffe Hospital, UK. clare.collins@paediatrics.ox.ac.uk
Abstract:
Neisseria meningitidis is one of the leading infectious causes of death in children under five years old in industrialized countries, and most cases can be attributed to five disease-causing serogroups: A, B, C, Y and W135. Meningococcal vaccine development began in the 1930s with killed whole-cell and exotoxin vaccines, but widespread use of polysaccharide vaccines did not begin until the 1970s. Serogroup A, C, Y and W135 polysaccharides are all included in vaccines for travellers, other high risk groups and control of outbreaks, but have limited immunogenicity and effficacy in childhood. Protein-polysaccharide conjugate vaccines overcome this problem and offer the possibility of protection in early childhoodfrom serogroup A, C, Y and W135. An effective serogroup B vaccine remains elusive and the greatest challengefor vaccine developers.
Insights
Meningococcal vaccines target serogroups A, C, Y, and W135, but an effective serogroup B vaccine for Neisseria meningitidis remains a challenge for child health.
Area of Science:
- Microbiology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Neisseria meningitidis is a major cause of infectious death in children under five in industrialized nations.
- Five serogroups (A, B, C, Y, W135) cause the majority of meningococcal disease cases.
- Early meningococcal vaccines (whole-cell, exotoxin, polysaccharide) had limitations, particularly in young children.
Purpose of the Study:
- To review the historical development and current challenges in meningococcal vaccine research.
- To highlight the efficacy of protein-polysaccharide conjugate vaccines against specific serogroups.
- To identify the ongoing difficulties in developing a serogroup B vaccine.
Main Methods:
- Review of historical vaccine development milestones.
- Analysis of polysaccharide and conjugate vaccine immunogenicity and efficacy data.
- Discussion of challenges in serogroup B vaccine development.
Main Results:
- Polysaccharide vaccines are available for serogroups A, C, Y, and W135, but show limited efficacy in young children.
- Protein-polysaccharide conjugate vaccines improve immunogenicity and offer protection against serogroups A, C, Y, and W135 in early childhood.
- An effective vaccine against serogroup B remains a significant hurdle.
Conclusions:
- While conjugate vaccines have advanced protection against several serogroups, a universal meningococcal vaccine, especially for serogroup B, is still needed.
- Further research is critical to overcome the challenges in developing a broadly protective and effective meningococcal vaccine for all age groups.
- Addressing the serogroup B vaccine gap is crucial for reducing childhood mortality from meningococcal disease.